Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 4803262, 5 pages
https://doi.org/10.1155/2017/4803262
Research Article

Clostridium difficile in Inflammatory Bowel Disease: A Retrospective Study

1Department of Medicine, University of Massachusetts School of Medicine, 55 Lake Avenue North, Worcester, MA 01604, USA
2Department of Gastroenterology, University of California Los Angeles, Los Angeles, CA, USA
3Department of Gastroenterology, Aurora Healthcare, Milwaukee, WI, USA
4Department of Medicine, University of Massachusetts, Worcester, MA, USA
5Department of Gastroenterology, University of Massachusetts, Worcester, MA, USA

Correspondence should be addressed to William Gillespie; gro.lairomemssamu@eipsellig.mailliw

Received 6 June 2017; Accepted 24 July 2017; Published 4 October 2017

Academic Editor: Paolo Gionchetti

Copyright © 2017 William Gillespie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. S. Magill, J. R. Edwards, W. Bamberg et al., “Multistate point-prevalence survey of health care associated infections,” The New England Journal of Medicine, vol. 370, pp. 1198–1208, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. J. G. Bartlett, T. W. Chang, M. Gurwith, S. L. Gorbach, and A. B. Onderdonk, “Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia,” The New England Journal of Medicine, vol. 298, no. 10, pp. 531–534, 1978. View at Publisher · View at Google Scholar
  3. J. F. Rodemann, E. R. Dubberke, K. A. Reske, D. H. Seo, and C. D. Stone, “Incidence of Clostridium difficile infection in inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 5, no. 3, pp. 339–344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. F. C. Lessa, Y. Mu, W. M. Bamberg et al., “Burden of Clostridium difficile infection in the United States,” The New England Journal of Medicine, vol. 372, no. 9, pp. 825–834, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. B. A. Miller, L. F. Chen, D. J. Sexton, and D. J. Anderson, “Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals,” Infection Control and Hospital Epidemiology, vol. 32, no. 4, pp. 387–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Zimlichman, D. Henderson, O. Tamir et al., “Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system,” JAMA Internal Medicine, vol. 173, no. 22, pp. 2039–2046, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. G. E. Bignardi, “Risk factors for Clostridium difficile infection,” The Journal of Hospital Infection, vol. 40, no. 1, pp. 1–15, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Khanna and D. S. Pardi, “IBD: poor outcomes after Clostridium difficile infection in IBD,” Nature Reviews Gastroenterology & Hepatology, vol. 9, no. 6, pp. 307-308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. N. Ananthakrishnan, E. L. McGinley, and D. G. Binion, “Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease,” Gut, vol. 57, no. 2, pp. 205–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. Centers for Disease Control and Prevention (CDC), “Severe Clostridium difficile-associated disease in populations previously at low risk – four states, 2005,” MMWR Morbidity and Mortality Weekly Report, vol. 54, no. 47, pp. 1201–1205, 2005. View at Google Scholar
  11. S. Khanna and D. S. Pardi, “The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings,” Expert Review of Gastroenterology & Hepatology, vol. 4, no. 4, pp. 409–416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Khanna, D. S. Pardi, S. L. Aronson et al., “The epidemiology of community-acquired Clostridium difficile infection: a population-based study,” The American Journal of Gastroenterology, vol. 107, no. 1, pp. 89–95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. H. Cohen, D. N. Gerding, S. Johnson et al., “Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA),” Infection Control and Hospital Epidemiology, vol. 31, no. 5, pp. 431–455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. G. C. Nguyen, G. G. Kaplan, M. L. Harris, and S. R. Brant, “A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients,” The American Journal of Gastroenterology, vol. 103, no. 6, pp. 1443–1450, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Issa, A. Vijayapal, M. B. Graham et al., “Impact of Clostridium difficile on inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 5, no. 3, pp. 345–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Soler, F. Nogareda, and R. Cano, “Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997-2005,” Infection Control and Hospital Epidemiology, vol. 29, no. 9, pp. 887–889, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Burckhardt, A. Friedrich, D. Beier, and T. Eckmanns, “Clostridium difficile surveillance trends, Saxony, Germany,” Emerging Infectious Diseases, vol. 14, pp. 691-692, 2008. View at Publisher · View at Google Scholar
  18. J. Lucado, C. Gould, and A. Elixhauser, “Clostridium difficile infections (CDI) in hospital stays, 2009: statistical brief #124,” Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Agency for Healthcare Research and Quality (US), Rockville (MD), 2006. View at Google Scholar
  19. K. R. Reveles, G. C. Lee, N. K. Boyd, and C. R. Frei, “The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010,” American Journal of Infection Control, vol. 42, no. 10, pp. 1028–1032, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. M. H. Wilcox, N. Shetty, W. N. Fawley et al., “Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England,” Clinical Infectious Diseases, vol. 55, no. 8, pp. 1056–1063, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. H. Wilcox, L. Mooney, R. Bendall, C. D. Settle, and W. N. Fawley, “A case-control study of community-associated Clostridium difficile infection,” Journal of Antimicrobial Chemotherapy, vol. 62, no. 2, pp. 388–396, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. P. K. Kutty, C. W. Woods, A. C. Sena et al., “Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA,” Emerging Infectious Diseases, vol. 16, pp. 197–204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. J. Lambert, M. Dyck, L. H. Thompson, and G. W. Hammond, “Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions,” Infection Control and Hospital Epidemiology, vol. 30, no. 10, pp. 945–951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Issa, A. N. Ananthakrishnan, and D. G. Binion, “Clostridium difficile and inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 14, no. 10, pp. 1432–1442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Das, P. Feuerstadt, and L. J. Brandt, “Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease,” The American Journal of Gastroenterology, vol. 105, no. 9, pp. 2040–2049, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Khanna and P. K. Tosh, “A clinician’s primer on the role of the microbiome in human health and disease,” Mayo Clinic Proceedings, vol. 89, no. 1, pp. 107–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Matsuoka and T. Kanai, “The gut microbiota and inflammatory bowel disease,” Seminars in Immunopathology, vol. 37, no. 1, pp. 47–55, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Schneeweiss, J. Korzenik, D. H. Solomon, C. Canning, J. Lee, and B. Bressler, “Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections,” Alimentary Pharmacology & Therapeutics, vol. 30, no. 3, pp. 253–264, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Kariv, U. Navaneethan, P. G. Venkatesh, R. Lopez, and B. Shen, “Impact of Clostridium difficile infection in patients with ulcerative colitis,” Journal of Crohn's & Colitis, vol. 5, no. 1, pp. 34–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Engel and M. F. Neurath, “New pathophysiological insights and modern treatment of IBD,” Journal of Gastroenterology, vol. 45, no. 6, pp. 571–583, 2010. View at Publisher · View at Google Scholar · View at Scopus